Related Experiment Video
Updated: Jun 25, 2025
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
Carcinoembryonic antigen potentiates non-small cell lung cancer progression via PKA-PGC-1ɑ axis
Juan Lei1, Lei Wu1,2, Nan Zhang2
1Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, 400030, China.
Molecular Biomedicine
|May 23, 2024
Summary
Carcinoembryonic antigen (CEA) promotes non-small cell lung cancer (NSCLC) growth and migration by enhancing fatty acid metabolism via the PKA-PGC-1α pathway. Targeting CEA or this pathway may offer new NSCLC therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Carcinoembryonic antigen (CEA) is a tumor-associated antigen involved in cancer progression.
- The exact mechanisms by which CEA drives tumor cell proliferation are not fully understood.
Purpose of the Study:
- To investigate the role of CEA in non-small cell lung cancer (NSCLC) proliferation and migration.
- To elucidate the molecular pathways linking CEA to cancer cell metabolism and growth.
Main Methods:
- Cell culture experiments using NSCLC cell lines (A549, H1299).
- Analysis of mitochondrial content, lipid droplet accumulation, and fatty acid metabolism.
- Investigation of the PKA-PGC-1α signaling pathway activation by CEA.
- In vitro and in vivo studies assessing the impact of pathway inhibition.
Main Results:
- CEA enhances NSCLC proliferation and migration while inhibiting cisplatin-induced apoptosis.
- CEA increases mitochondrial numbers and lipid droplets, indicating altered fatty acid metabolism.
- CEA activates the PKA-PGC-1α pathway by increasing intracellular cAMP levels.
- Inhibition of fatty acid metabolism or the PKA-PGC-1α pathway reduces CEA-mediated NSCLC progression.
Conclusions:
- CEA promotes NSCLC proliferation and migration by modulating fatty acid metabolism through the PKA-PGC-1α signaling pathway.
- Targeting CEA or the PKA-PGC-1α pathway presents a potential therapeutic strategy for NSCLC.
Related Concept Videos
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
01:25cAMP-dependent Protein Kinase Pathways
6.3K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.3K
01:22PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
01:58Cell Specific Gene Expression
13.6K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.6K
01:07MAPK Signaling Cascades
5.4K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.4K